Release no 27/2010

Copenhagen and Oslo, 19th August, 2010

Affitech A/S, (NASDAQ OMX: AFFI), the antibody medicines company, announced this
morning that the Company today on 19th August, 2010 will publish a prospectus in
connection with the admission to trading and official listing on NASDAQ OMX
Copenhagen of 260,187,010 already issued shares of DKK 0.50 nominal value each.
The shares were issued on April 22nd, 2010 and registered in VP SECURITIES A/S
on May 27th to Trans Nova Investment Limited.

In this prospectus the following financial information will be disclosed:

Capitalisation and Debt
The table below contains an overview of the Affitech Group's capital and debt at
March
31st, 2010 and May 31st, 2010.

Table: Capitalisation and Debt
--------------------------------------------------------------------------------
--------------------------------------------------------------------------------
| DKK ‘000 | As of March 31st, | As of May 31st, |
| | 2010 | 2010 |
--------------------------------------------------------------------------------
--------------------------------------------------------------------------------
| Share capital | 71,778 | 201,871 |
--------------------------------------------------------------------------------
| Share premium | 154,897 | 180,916 |
--------------------------------------------------------------------------------
| Other reserves | (231,680) | -240,479 |
--------------------------------------------------------------------------------
| Total equity | -5,005 | 142,308 |
--------------------------------------------------------------------------------
--------------------------------------------------------------------------------
--------------------------------------------------------------------------------
--------------------------------------------------------------------------------
| Non-current liabilities | 1,795 | 1,763 |
--------------------------------------------------------------------------------
| Current liabilities | 34,643 | 20,536 |
--------------------------------------------------------------------------------
| Total liabilities | 36,438 | 22,298 |
--------------------------------------------------------------------------------

The Company has no secured or guaranteed debt.
Non-current liabilities include debt of DKK 1.5 million at March 31st, 2010 and
at May 31st, 2010 relating to a finance lease. Current liabilities at March
31st, 2010 includes the bridge loan provided by three existing shareholders
announced January 4th, 2010, including accrued interests and fees at DKK 15.7
million, the loan was repaid in May, 2010. Other than as stated above, there was
no interest-bearing debt as at March 31st, 2010 or at May 31st, 2010. The above
figures as per March are from the quarterly report for the first quarter of 2010
and the figures as per May are from Affitech's internal financial reporting. The
figures as per May include the directed offering with Trans Nova from April
21st, 2010.

--------------------------------------------------------------------------------
| For more information please contact Affitech A/S: |
--------------------------------------------------------------------------------
| Martin Welschof, Managing Director | Randi Krogsgaard, IR & Corporate
|
| | Communications |
| Tel # +47 95 12 81 37 | Tel # +45 2320 1001, e-mail: |
| | [email protected] |
--------------------------------------------------------------------------------

About Affitech
Affitech AS is a publicly traded (NASDAQ OMX Copenhagen) human therapeutic
antibody company headquartered in Copenhagen, Denmark with R&D facilities in
Oslo, Norway. The company utilizes a range of proprietary antibody technologies
for the discovery of fully human antibodies for application in oncology,
inflammation and other disease areas. CBAS™ (Cell Based Antibody Selection) is
Affitech's premier discovery engine for the isolation of lead antibodies to cell
surface molecules in situ. Several of the Company's proprietary product
candidates were generated by CBAS™. Further information is available at
www.affitech.com.

Disclaimer
This news release contains forward-looking statements and forecasts
based on uncertainty, since they relate to events and depend on circumstances
that will occur in the future and which, by their nature, will have an impact on
results of the financial condition and operations of Affitech A/S. There are
many factors that could cause actual results and developments to differ
materially from those expressed or implied by these forward-looking statements
and forecasts. These factors include, among other things, risks associated with
technological development, the risk that research & development will not yield
new products that achieve commercial success, the impact of competition, the
ability to transact viable and profitable commercial deals, the risk of
non-approval of patents not yet granted, and difficulties of obtaining relevant
governmental approvals for new products.
No expressed or implied representations or warranties are given concerning
Affitech A/S or the accuracy or completeness of the information provided herein,
and no claims shall be made by the recipient of this news release by virtue of
the information contained herein.

100819_disclosure_of_financial_information_pr 27_uk.pdf